Currently , Dr Sanjay Singh is the Chief Executive Officer & Whole-time Director of Gennova Biopharmaceuticals , a subsidiary of Emcure Pharmaceuticals . Before he set up Gennova in 2006 , Dr Singh ’ s drive to develop treatments for diseases like malaria and his tenure at the International Center for Genetic Engineering and Biotechnology ( ICGEB ) led to a stint at The National Institutes of Health ( NIH ) in the US . Apart from heading the antigen research section at NIH ' s National Institute of Allergy and Infectious Diseases for a few years , he helped progress four recombinant vaccine candidates to Phase I clinical trials . He has won numerous awards from the US Department of Human and Health Services , some of which include ‘ Special Act or Service Award ’ in 2005 and ‘ Staff Recognition Award , NIAID-NIH ’ in 2004 .
Dr . Singh hold a masters degree in biochemistry from the Lucknow University and is a Ph . D . in biochemistry from the Central Drug Research Institute , Lucknow .
At Gennova , Dr . Singh ’ s leadership has facilitated the launch of various therapeutic life-saving biologics in the cardiovascular , renal care and oncology market . His focus on innovations in bio-manufacturing technologies has made the drugs affordable to the masses and today , under his guidance Gennova is the market leader in four of its products . Two of the biosimilars ( Tenecteplase and Pegaspargase ) launched were the first biosimilar to be launched globally . Realizing the potential of the use of Tenecteplase for stroke , Dr Singh pioneered its approval for acute ischemic stroke – the first time globally .
Under his guidance , Gennova has diversified into vaccine research specifically in the area of infectious diseases , in particular Malaria , HPV , Leishmaniasis and Tuberculosis in partnership with various national and global organizations . His commitment to this filed is accentuated by the fact that today Gennova is the only supplier of cGMP grade vaccine adjuvant GLA-SE , which has proven successful in the recently concluded Ph1 CT for a malaria vaccine candidate .
Current Position : Chief Executive Officer & Whole-time Director , Gennova Biopharmaceuticals
Impact : Pioneered drug approval for acute ischemic stroke for first time globally . Played important role during COVID-19 pandemic .
Notable Awards : ‘ Special Act or Service Award ’ in 2005 and ‘ Staff Recognition Award , NIAID / NIH ’ in 2004
Alma Mater : Lucknow University ; Central Drug Research Institute , Lucknow
Dr Singh is a member of the Central Drugs Standard Control Organization ( CDSCO ), Drug Controller General of India ( DCGI ) for development of the Indian Guidelines on Similar Biologics ( Regulatory Requirements for Marketing Authorization ). He also serves as a member of the Governing body of the Institute of Life Sciences ( ILS ) – Bhubaneswar , an autonomous institute of DBT . Additionally , he is part of the working group for Gene Therapy constituted jointly by the Department of Health Research ( DHR ) and DBT .
BioTech
BIOVOICENEWS . COM 41